Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD10 | O75832 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427945 | 0.82 | KMT2A (0.39) | CA12CA1CA2CA9KCNH2 | |
| SCHEMBL941807 | 0.81 | MMP2 (0.43) | PSMD10CA12CA1CA2CA9 | |
| SCHEMBL14042903 | 0.75 | MMP2 (0.38) | PSMD10CA12CA1CA2CA9 | |
| SCHEMBL16367292 | 0.74 | KMT2A (0.54) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL16367296 | 0.73 | KMT2A (0.47) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL16367345 | 0.72 | L3MBTL1 (0.38) | KMT2ALMNATHRB | |
| SCHEMBL943760 | 0.72 | CA12 (0.51) | PSMD10CA12CA1CA2CA9 | |
| SCHEMBL16367365 | 0.72 | MMP2 (0.36) | MMP2MMP9KMT2ALMNATHRB | |
| SCHEMBL16367349 | 0.71 | EGFR (0.37) | PSMD10KMT2ALMNATHRB | |
| SCHEMBL16367353 | 0.71 | EGFR (0.52) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2132200-B1 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977361-B2 | Nitro-imidazole hypoxia imaging agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807394-B2 | Nitro-imidazole hypoxia imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2132200-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | Siemens Medical Solutions USA, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008124651-A2 | NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010846-A1 | Nitro-Imidazole Hypoxia Imaging Agents | HIF1AN, HIF1A, HYOU1 | PSMD10 4042/4885CA12 453/4885CA1 128/4885 |
| US-20110002850-A1 | Nitro-Imidazole Hypoxia Imaging Agent | HIF1AN, HIF1A, HYOU1 | PSMD10 3995/4885CA12 414/4885CA1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.